UPstart Program Selects Clinlogix as a CRO Partner
Clinlogix, a clinical research organization located just outside Philadelphia, is proud to announce its selection by the UPstart program at the University of Pennsylvania as a preferred Clinical Research Organization. The UPstart program strives to maximize the potential of University of Pennsylvania research and technologies through the creation and stimulus of entrepreneurial endeavors. Clinlogix is extremely excited about this partnership, which allows the company to leverage its extensive clinical and regulatory experience and transfer that knowledge to a variety of UPSTART projects.
Michael Poisel, UPstart Director, stated that “So much of the success of our UPstart companies is determined by the involvement of our many partners along the way. We are excited to have the Clinlogix team join us and add their significant experience in the development of these exciting young businesses.”
JeanMarie Markham, President and CEO of Clinlogix, stated that “The relevance of this relationship is the recognition that early stage, academic research is beginning to think beyond its borders. Historically there have been challenges in the process of ‘translating’ academic research and concepts into a ‘commercial’ product and viable company. The selection of Clinlogix by UPstart reflects the organization’s forward thinking. UPstart is beginning with the end in mind. With limited financial resources, the goal is to make the most impact by developing viable strategic development plans. “
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
